MedTrace Logo

Program for the Introduction Into Clinical Practice of the Principles of Personalized and Preventive Medicine Based on the Isolation of Gene Polymorphism in Schizophrenia in People of the Kazakh Ethnic Group

NCT05090644 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 700

Last updated 2023-03-14

No results posted yet for this study

Summary

This is a GWAS study that aims to identify possible candidate genes associate to schizophrenia by exploring single nucleotide polymorphism (SNP) in a group of schizophrenia, in the Kazakh population. The investigators hypothesize that the careful phenotyping of the subject sand matching with increase the power to find SNP significantly associated with schizophrenia

Conditions

Interventions

GENETIC

DNA analysis

GWAS

Sponsors & Collaborators

  • Asfendiyarov Kazakh National Medical University

    lead OTHER

Principal Investigators

  • Kuanysh Altynbekov, PhD · Republican Scientific and Practical Center for Mental Health

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-03-30
Primary Completion
2023-01-20
Completion
2023-01-20

Countries

  • Kazakhstan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05090644 on ClinicalTrials.gov